Multiple myeloma trials in France

In France 92 Also abroad 705

78 of 92 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
Where
Angers, Brest, Caen, Nantes, Rennes, Tours
Age
18 years and over
People
35
Run by
Nantes University Hospital
See details and how to joinNCT03832127
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Bayonne, Créteil, Dunkerque, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Nantes, Nice, Paris, Pessac, Poitiers, Pontoise, Quimper Cedex, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, Vannes
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1Active, not recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Creteil Cedex, Marseille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
250 worldwide
Run by
AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00
Phase 3Not yet taking people in France
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Lille Cedex, Nantes, Nice, Pierre-Bénite, Poitiers, Toulouse, Vandoeuvre Les Nancy
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Active, not recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Lyon, Paris, Pessac, Villejuif
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1Taking people
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Where
Angers, Creteil Cedex, Lille, Montpellier Cedex 5, Nantes, Paris, Poitiers, Villejuif
Age
18 years and over
People
317 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00
Phase 1/2Taking people
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Where
Pierre-Bénite, Toulouse Cedex 9, Tours Cedex 9, Villejuif
Age
18 years and over
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00
Phase 3Not yet taking people in France
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Argenteuil Cedex, Chambéry, Lyon, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, Villejuif
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Not yet taking people in France
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Angers, Cannes Cedex, Lille Cedex, Lyon, Montpellier Cedex 5, Nantes, Paris, Paris Cedex 13, Pessac Cedex, Poitiers, Rouen Cedex, Saint-Cloud, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
Phase 2Active, not recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Creteil Cedex, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Toulouse Cedex 9
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Lille Cedex, Nantes, Paris, Pierre-Bénite, Poitiers
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Creteil, Dijon, Lille, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Strasbourg, Strasbourg Cedex 2, Toulouse Cedex 9
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Nantes, Pierre-Bénite, Rennes, Toulouse
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Creteil, Lille, Nancy Cedex, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Toulouse Cedex 9, Tours
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 2Taking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Argenteuil, Bayonne, La Tronche, Le Mans, Nantes, Quimper
Age
18 years and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Lille, Montpellier, Nantes, Paris, Pessac, Pierre-Bénite, Toulouse, Tours, Vandœuvre-lès-Nancy
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Active, not recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Clermont-Ferrand, Lille, Limoges, Lyon Cedex08, Nantes, Nîmes, Paris, Pessac, Strasbourg, Tours
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Lille, Nantes
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 2Taking people
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Where
Bayonne, Marseille, Pierre-Bénite, Rouen Cedex, Toulouse Cedex 9, Tours, Villejuif
Age
18 years and over
People
100 worldwide
Run by
C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Créteil Cedex, Lille Cedex, Nantes, Paris, Pierre-Bénite
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Nantes, Nice, Paris Cedex 12, Poitiers, Toulouse Cedex 9, Tours, Villejuif
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Montpellier Cedex 5, Nantes, Paris, Poitiers, Toulouse
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 1/2Completed
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Lille Cedex, Nantes, Poitiers
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
Phase 1Taking people
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Where
Lille Cedex, Nantes, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
165 worldwide
Run by
K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00
Phase 3Not yet taking people in France
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Lille, Nantes, Paris, Toulouse
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637